Cytiva, 17550001, Mag Sepharose™ PrismA magnetic bead resin

Mag Sepharose™ PrismA, 25 mL
Mag Sepharose™ PrismA magnetic bead resin uses a genetically engineered protein A-derived ligand immobilized to Mag Sepharose™ beads for capture of target proteins followed by collection of the beads using a magnetic device.
• Can be used for high-throughput screening of antibody drug candidates in microwell plates and for purification of antibodies in a magnetic separator.
• Magnetic properties that reduce materials and workload for antibody screening in microwell plates.
• Capture of mAbs in up to 80 L of unfiltered feed eliminates clarification steps in antibody processes.
• Excellent alkaline stability enables efficient cleaning and sanitization using 0.5–1.0 M NaOH for improved process economy and robustness.
Principles of magnetic separation The paramagnetic properties of the resin allow it to adhere to magnets for easy extraction of the beads from a solution or suspension. When combined with the protein A-derived PrismA ligand, the resin can capture high amounts of mAbs, which can then be washed and eluted by magnetic separation. Mag Sepharose™ PrismA resin can be applied directly to an unfiltered cell suspension for capture and elution of mAbs. It can also be used for automated screening of antibody drug candidates, in which the resin is moved across wells in a microwell plate, and the beads are extracted magnetically. This saves both time and material.
High-throughput antibody drug candidate screening capabilities To perform screening using Mag Sepharose™ PrismA, load resin in a deep-well plate. Use a robotic liquid handling system to prepare buffers and add them to the plates. Perform capture of the target molecule using a robotic magnetic separator to transfer beads between the wells of the plate. High-productivity mAb capture directly from feed A cell feed can be applied directly to the Mag Sepharose™ PrismA resin for bioprocess purification of antibodies, eliminating the need for several clarification steps compared to a traditional mAb process. This also allows for dense cell cultures and high mAb titers upstream, as clarification before capture is not needed.